Washington, D.C. 20549




Current Report


Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 9, 2015



(Exact name of registrant as specified in its charter)


Delaware   1-16467   33-0303583
(State or other jurisdiction   (Commission   (I.R.S Employer
of incorporation)   File Number)   Identification No.)


126 Valley Road, Suite C

Glen Rock, New Jersey

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (201) 444-4947



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 7.01 Regulation FD Disclosure


On January 9, 2015, Cortex Pharmaceuticals, Inc. (the “Company”) announced that the Company’s Executive Chairman and CEO, Dr. Arnold S. Lippa, Ph.D., will be presenting at Biotech Showcase 2015TM at the Parc 55 Wyndham San Francisco-Union Square Hotel. Dr. Lippa is currently scheduled to present at 4:30 p.m. Pacific Standard Time on Tuesday, January 13, 2015. The slide presentation that the Company will be using at the conference is attached as Exhibit 99.1 and is being furnished and not filed pursuant to Item 7.01 of Form 8-K.


Item 8.01 Other Events


The information provided in Item 7.01 is incorporated herein by reference. The presentation will be available by live webcast that can be accessed by clicking on the investors tab on the Company’s web-site ( and following the links and instructions or by going to The press release announcing the Company’s participation in the conference is attached as Exhibit 99.2.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits.


A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Date: January 13, 2015    
  By: /s/ Arnold S. Lippa
    Arnold S. Lippa
    President and Chief Executive Officer






Exhibit Number   Exhibit Description
99.1   Slide Presentation (furnished herewith).
99.2   Press Release dated January 9, 2015.








































































































Exhibit 99.2


Cortex Pharmaceuticals, Inc. to Present at 7th Annual Biotech Showcase 2015™


CEO to Present Strategic Initiatives in Respiratory Disorders and Key Objectives


Glen Rock, N.J., Jan. 9, 2015/Globe Newswire – Cortex Pharmaceuticals, Inc. (CORX) (“Cortex” or the “Company”), a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at Biotech Showcase 2015™ ( The conference is co-sponsored by the EBD Group and Demy-Colton Life Sciences Advisors and will be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, California from January 12 – 15, 2015.


The Company’s Executive Chairman and CEO, Dr. Arnold S. Lippa, Ph.D., is currently scheduled to present at 4:30 p.m. Pacific Standard Time on Tuesday, January 13, 2015. Dr. Lippa will present details of Cortex’s initiatives with dronabinol for obstructive sleep apnea (Phase - IIB), CX-1739 (oral) for drug-induced respiratory depression and central sleep apnea (both Phase - IIa), and CX-1942 (injectable) for drug-induced respiratory depression (preclinical), as well as background data.


The conference is attended by public companies, institutional investors, industry executives, private equity firms, private companies, venture capitalists, business development executives and sophisticated private investors.


The presentation will be available by live webcast streaming online. To access the live audio webcast, log onto Cortex’s website at, click on the investors tab and follow the links and instructions, or go to A copy of the slide presentation to be presented at the conference will be filed with the Securities and Exchange Commission in a Current Report on Form 8-K prior to the presentation and will also be available in the investors section of Cortex’s website.


About Cortex Pharmaceuticals, Inc.


Cortex Pharmaceuticals, Inc. is a biopharmaceutical company currently engaged in the discovery and development of drugs for the treatment of respiratory disorders. Drug candidates are currently derived from two platforms, as described below.




The first platform is a class of compounds known as ampakines that act as positive allosteric modulators of AMPA glutamate receptors. Several ampakines in both oral and injectable form are being developed by Cortex for the treatment of drug induced respiratory depression caused by opiates and anesthetics. In preclinical and clinical studies, such drugs have shown preliminary efficacy in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects of drugs such as propofol. The Company’s compounds belong to a new generation of ampakines that do not display the undesirable side effects displayed by previous compounds.


The second platform is the class of compounds known as cannabinoids, in particular, dronabinol. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol significantly improved measures of sleep apnea in a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B study is currently being conducted by the University of Illinois and is being funded by the National Institutes of Health.


Additional information about Cortex and the matters discussed herein can be obtained on the Company’s website at or in the Company’s filings on EDGAR at


Special Note Regarding Forward-Looking Statements: Certain statements included or incorporated by reference in this news release, including information as to the future financial or operating performance of the Company and its drug development programs, constitute forward-looking statements. The words “believe,” “expect,” “anticipate,” “contemplate,” “target,” “plan,” “intend,” “continue,” “budget,” “estimate,” “may,” “schedule” and similar expressions identify forward-looking statements. Forward-looking statements include, among other things, statements regarding future plans, targets, estimates and assumptions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, the Company. Due to these various risks and uncertainties, actual events may differ materially from current expectations. Investors are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Forward-looking statements are made as of the date of this news release and the Company disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or results or otherwise.


Company Contact:


Jeff Margolis

Vice-President and Secretary

Telephone: (917) 834-7206